Skip to main
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo is supported by accelerating commercialization, with fiscal Q2 2026 revenue of $11.7 million, up 21% year over year and above expectations, while EPS of $(0.09) also beat estimates. The business is gaining structural support from the March 2024 CMS ruling that expanded Medicare Part B reimbursement for MyoPro, helping drive 211 units sold in Q2 and a reimbursement pipeline of 1,491 alongside backlog of 218. Management’s raised 2026 revenue guidance to $45–47 million, plus strong U.S. O&P growth of 130% in Q2 and 32% international revenue growth, reinforces a positive outlook.

Bears say

Myomo is burdened by balance sheet and liquidity risk, with cash declining to $16 million from $18 million at the end of December while debt remained $11 million, leaving limited flexibility if commercialization or reimbursement progress stalls. Its outlook is further weakened by dependence on successful product adoption, maintaining regulatory approvals, and securing suitable insurance reimbursement, all of which are uncertain for a wearable medical robotics company that still faces commercialization execution risk. Competitive pressure, macroeconomic headwinds, and shifting investor, consumer, or government priorities for healthcare could further constrain demand and sentiment, making the stock fundamentally vulnerable despite its FDA-registered MyoPro device.

Myomo (MYO) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Oct 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.